B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo

Blood

Volumn 99, Issue 8, 2002, Pages 2880-2889

  Bai, Xue Feng ^a,b   Liu, Jinqing ^a,b   May Jr , Kenneth F ^a,b   Guo, Yong ^a,b   Zheng, Pan ^a,b   Liu, Yang ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; FLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0037089410     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.8.2880     Document Type: Article

References (59)

1. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
2. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1
3. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production
4. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation
5. B70 antigen is a second ligand for CTLA-4 and CD28
6. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7
7. CTLA-4 is a second receptor for the B cell activation antigen B7
8. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
9. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules
10. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
11. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells
12. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
13. Enhancement of antitumor immunity by CTLA-4 blockade
14. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
15. CTLA-4 can function as a negative regulator of T cell activation
16. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
17. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
18. Thymocyte development is normal in CTLA-4-deficient mice
19. Molecular basis of T cell inactivation by CTLA-4
20. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4
21. Cytotoxic Tlymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes
22. Acquired thymic tolerance: Role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model
23. Is CTLA-4 a negative regulator for T-cell activation?
24. Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells
25. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses
26. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade: Heterogeneity within the human T-cell population
27. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail
28. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28
29. The role of B7-CD28 co-stimulation in tumor rejection
30. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection
31. Absence of B7-dependent responses in CD28-deficient mice
32. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: A paradigm reconsidered
33. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion
34. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge
35. Cytotoxic T lymphocytes to an unmutated tumor antigen P1A: Normal development but restrained effector function
36. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells
37. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain
38. The murine homologue of the T lymphocyte antigen CD28: Molecular cloning and cell surface expression
39. The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis
40. Determination of lymphocyte division by flow cytometry
41. Regulation of surface and intracellular expression of CTLA4 on mouse T cells
42. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement
43. Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability
44. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4
45. Duration of TCR stimulation determines costimulatory requirement of T cells
46. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen
47. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens
48. Negative selection of CD4+CD8+ thymocytes by T cell receptor-induced apoptosis requires a costimulatory signal that can be provided by CD28
49. Differing roles for B7 and intercellular adhesion molecule-1 in negative selection of thymocytes
50. The emerging role of CTLA-4 as an immune attenuator
51. T cell activation determined by T cell receptor number and tunable thresholds
52. CTLA4-g prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice
53. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
54. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo
55. CD4(+) T cells eliminate MHC class 11-negative cancer cells in vivo by indirect effects of IFN-gamma
56. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody
57. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
58. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
59. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes